Editor
======

Colorectal cancer (CRC) is the second most common cause of cancer-related death[@b1]. Inherited genetic factors are significant in \<30% of cases. In \~5% of all cases[@b2], CRC is associated with a highly penetrant dominant or recessive inherited syndrome. The most common of these is Lynch syndrome ( hereditary non-polyposis colorectal cancer, HNPCC), an autosomal dominant cancer susceptibility syndrome caused by a germline mutation in one of the DNA mismatch repair (MMR) genes, namely MLH1, MSH2, MSH6 or PMS2. Affected individuals have a predisposition to developing early onset CRC and a range of other cancers, particularly endometrial in females. The associated lifetime cancer risk is 75%[@b2]. Early diagnosis enables at risk family members to be enrolled in appropriate cancer surveillance programmes, thus reducing mortality and morbidity. Additionally, recent studies have indicated a role for aspirin in reducing Lynch syndrome tumours[@b3].

MMR defect leads to instability in microsatellites of tumour DNA. This feature can be found in \>90% of colon cancers associated with Lynch syndrome, compared to \~ 15% of cases of sporadic CRC[@b2]. Using immunohistochemistry (IHC), tumour analysis with antibodies against the four MMR proteins demonstrates loss of protein expression of the causative gene. This investigation thereby provides early, valuable identification of possible HNPCC-related tumours. It furthermore directs germline mutation screening to the gene involved, significantly reducing the time and cost involved in searching for a causative mutation and prioritising families in which this limited resource should be applied. When individuals are identified with a germline MMR mutation, there are implications for long term screening requirements and possible prophylactic gynaecological surgery to reduce cancer risk[@b4]. Germline mutation identification also allows predictive testing for at risk family members.

Currently the Amsterdam criteria II and revised Bethesda guidelines are used to identify families with potential Lynch syndrome for further investigation ([Box 1](#bx1){ref-type="boxed-text"}). MMR IHC provides key information in this assessment. Delay in the time taken to obtain IHC results negatively impacts upon the overall time to obtain germline mutation screening results. While awaiting germline mutation screening, individuals and their relatives may either not access appropriate screening or may undergo serial, unnecessary screening with associated risks and anxieties.

The authors performed a study to assess current regional practice in utilising MMR IHC[@b5]. 32 patients were identified with abnormal MMR IHC. Of these, six fulfilled Amsterdam criteria II and 26 fulfilled revised Bethesda criteria. 23 had CRC at an average age of 48 years (range 32-76). 11 had endometrial cancer at an average age of 56 years (range 36-67). The median wait for MMR IHC result was 69 days from time of request (range 1-588 days). Causes of delay included time required to locate appropriate pathology records, request pathology tissue for testing (from a range of pathology laboratories) and perform and interpret the assay. In 26 of 32 cases, IHC was requested by the clinical genetics team at the time of first genetics clinic appointment.

We would encourage our surgery and pathology colleagues to consider the diagnosis of Lynch syndrome and adopt the practice of requesting MMR IHC (where cases fulfill revised Bethesda criteria) at the time of surgery or prior to referral to clinical genetics, in order to streamline the investigation of possible Lynch syndrome and expedite germline mutation identification in such families.

Box 1 Amsterdam criteria II and revised Bethesda guidelines [\*\*](#fn2){ref-type="fn"}
---------------------------------------------------------------------------------------

[Amsterdam criteria II]{.ul}

There should be at least three relatives with colorectal cancer (CRC) or with a Lynch syndrome-associated cancer: cancer of the endometrium, small bowel, ureter or renal pelvis.

-   one relative should be a first-degree relative of the other two,

-   at least two successive generations should be affected,

-   at least one tumour should be diagnosed before the age of 50 years,

-   familial adenomatous polyposis (FAP) should be excluded,

-   tumours should be verified by histopathological examination.

[Revised Bethesda guidelines]{.ul}

1.  CRC diagnosed in a patient aged \<50 years.

2.  Presence of synchronous, metachronous colorectal or other Lynch syndrome-related tumours[\*](#fn1){ref-type="fn"}, regardless of age.

3.  CRC with MSI-H phenotype diagnosed in a patient aged \<60 years.

4.  Patient with CRC and a first-degree relative with a Lynch syndrome-related tumour, with one of the cancers diagnosed at age \<50 years.

5.  Patient with CRC with two or more first-degree or second-degree relatives with a Lynch syndrome-related tumour, regardless of age.

Lynch syndrome-related tumours include colorectal, endometrial, stomach, ovarian, pancreas, ureter, renal pelvis, biliary tract and brain tumours, sebaceous gland adenomas and keratoacanthomas, and carcinoma of the small bowel.

Reproduced from Vasen H I et al: Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). Journal of Medical Genetic 44; 353-362 (2007) with permission from BMJ Publishing Group Ltd.

The authors have no conflict of interest.
